Benefit-risk balance of hormone replacement therapy: Cancers and mortality. Postmenopausal women management- CNGOF and GEMVi clinical practice guidelines

被引：2
|
作者：
Poudou, C. [1 ]
Baffet, H. [2 ,3 ]
Nadeau, C. [1 ]
Rolland, A-L [2 ,3 ]
Catteau-Jonard, S. [2 ,4 ]
Robin, G. [2 ,4 ]
机构：
[1] CHU Poitiers, Serv Gynecol Obstet & Med Reprod, 2 Rue Miletrie, F-86021 Poitiers, France
[2] CHU Lille, Serv Gynecol Med Orthogenie & Sexol, Hop Jeanne de Flandre, Ave Eugene Avinee, F-59073 Lille, France
[3] CHU Lille, Serv Assistance Med Procreat & Preservat Fertilit, Ave Eugene Avinee, F-59037 Lille, France
[4] Univ Lille, Fac Med, 2 Ave Eugene Avinee, F-59120 Loos, France
来源：
GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE | 2021年 / 49卷 / 05期
关键词：
Hormone replacement therapy (HRT); Breast cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Mortality; ESTROGEN PLUS PROGESTIN; ENDOMETRIAL CANCER; OVARIAN-CANCER; REPRODUCTIVE FACTORS; ESOPHAGEAL CANCER; COLORECTAL-CANCER; BREAST-CANCER; HEALTH; COHORT; INTERVENTION;
D O I：
10.1016/j.gofs.2021.03.031
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
The use of hormone replacement therapy (HRT) for menopausal women has been the subject of much controversy in recent years, particularly concerning the carcinologic risks. The purpose of this review is to evaluate the impact of the use of HRT on the risk of gynecological but also extra-gynecological cancers. The effect of the type and the duration of use of HRT in menopausal women will also be discussed. The beneficial impact of HRT on overall mortality is also an element that will be discussed and must be taken into account when evaluating the benefit-risk balance of HRT for menopausal women. (c) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：462 / 473
页数：12
相关论文
共 27 条
  • [11] Management of vulvovaginal atrophy: Physical therapies. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Maris, E.
    Salerno, J.
    Hedon, B.
    Mares, P.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 414 - 419
  • [12] Effects of physical activity and decreased sedentary behaviours in menopausal women. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Duclos, M.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 335 - 348
  • [13] Non-hormonal alternatives for the management of menopausal hot flushes. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Raccah-Tebeka, B.
    Boutet, G.
    Plu-Bureau, G.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 373 - 393
  • [14] The HRT follow-up consultation. What to do in case of breast pain. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Mathelin, C.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 493 - 499
  • [15] The HRT follow-up consultation. What to do in case of breast tumour (clinical or radiological) and microcalcifications. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Mathelin, C.
    Moliere, S.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 485 - 492
  • [16] Hormone Replacement Therapy in Postmenopausal Women With Diabetes MellitusA Risk-Benefit Assessment
    Björn Andersson
    Drugs & Aging, 2000, 17 : 399 - 410
  • [17] Hormone replacement therapy in postmenopausal women with diabetes mellitus - A risk-benefit assessment
    Andersson, B
    DRUGS & AGING, 2000, 17 (05) : 399 - 410
  • [18] Hormone replacement therapy in postmenopausal women at cardiovascular risk: epidemiology and clinical trials
    Simon, T
    Jaillon, P
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2000, 2 (0G) : G2 - G6
  • [19] Management of postmenopausal women: Coll`ege National des Gynecologues et Obstetriciens Fran?ais (CNGOF) and Groupe d'Etude sur la Menopause et le Vieillissement (GEMVi) Clinical Practice Guidelines
    Tremollieres, F. A.
    Chabbert-Buffet, N.
    Plu-Bureau, G.
    Rousset-Jablonski, C.
    Lecerf, J. M.
    Duclos, M.
    Pouilles, J. M.
    Gosset, A.
    Boutet, G.
    Hocke, C.
    Maris, E.
    Hugon-Rodin, J.
    Maitrot-Mantelet, L.
    Robin, G.
    Andre, G.
    Hamdaoui, N.
    Mathelin, C.
    Lopes, P.
    Graesslin, O.
    Fritel, X.
    MATURITAS, 2022, 163 : 62 - 81
  • [20] Hormone replacement therapy and family history of breast cancer in a large prospective study of postmenopausal women: Increased risk of breast cancer but decreased total mortality.
    Sellers, TA
    Mink, PJ
    Anderson, KE
    Cerhan, JR
    Zheng, W
    Kushi, LH
    Folsom, AR
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1996, 143 (11) : 166 - 166
123